A5012987601- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Brain Metastases and Treatment
- Pancreatic and Hepatic Oncology Research
- Breast Cancer Treatment Studies
- Global Cancer Incidence and Screening
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Patient-Provider Communication in Healthcare
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- CAR-T cell therapy research
- Thyroid Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Vascular Tumors and Angiosarcomas
- Statistical Methods in Clinical Trials
- Patient Dignity and Privacy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA modifications and cancer
- BRCA gene mutations in cancer
- Inflammatory Biomarkers in Disease Prognosis
- Protein Degradation and Inhibitors
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
Princess Margaret Cancer Centre
2023-2025
Vitalité Health Network
2024-2025
Dr. Georges-L.-Dumont University Hospital Centre
2024-2025
University Health Network
2023-2024
University of Toronto
2023-2024
Universidade Federal Fluminense
2024
Universidade Federal do Rio de Janeiro
2024
Universidade Federal do Ceará
2024
Hospital Sírio-Libanês
2020-2023
Hospital São Paulo
2023
Abstract Background Brain metastasis (BrM) and Leptomeningeal Carcinomatosis (LMC) are uncommon complications in gastroesophageal carcinoma (GEC) patients. These patients have a poor prognosis challenging to treat. We described the clinicopathologic features outcomes largest cohort of Central Nervous System (CNS) GEC Methods single-center retrospective study treated from 2007 2021. Clinicopathologic characteristics treatment modalities were reviewed. Survival was calculated date CNS...
Hereditary breast cancer (BC) corresponds to 5% of all BC and a larger parcel early-onset disease. The incorporation next-generation sequencing (NGS) techniques reduced the cost molecular testing allowed inclusion additional predisposition genes in panels that are more comprehensive. This enabled identification germline pathogenic variants carriers introduction risk-reducing strategies. It also resulted co-occurrence than one variant some families. is rare event, there few reports on its...
708 Background: In early-stage cancer, overall survival (OS) is the gold-standard endpoint for assessing therapeutic efficacy. However, long follow-up periods make OS challenging and costly to measure in clinical trials. Disease-free (DFS), which captures time recurrence or death, has been proposed as a surrogate pancreatic cancer (PC). This surrogacy relationship could allow more rapid assessment of treatment benefits, but its validity requires robust analysis across Understanding...
The Eastern Canadian Gastrointestinal Cancer Consensus Conference was an annual meeting that held in St. John’s, Newfoundland and Labrador, from 26 to 28 September 2024. This included experts medical oncology, radiation surgical nuclear medicine, general practitioners oncology (GPO) across the eastern provinces who are involved management of patients with gastrointestinal malignancies. consensus statement generated by conference addresses multiple topics, including localized rectal cancer,...
Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 20-25 of patients with advanced gastroesophageal adenocarcinoma (GEA). Upon progression on 1st line therapy, ramucirumab and paclitaxel (rampac) given ≥2 setting regardless HER2 status. We aim to assess whether associated better survival positive(+) pts compared those HER2(-) disease. reviewed all consecutive adult metastatic/unresectable GEA who were treated rampac for ≥2nd therapy at Princess...
Objective Disease-free survival (DFS) is frequently used as the primary endpoint in trials of adjuvant and neoadjuvant therapies for early-stage pancreatic cancer (PC), but its validity a surrogate overall (OS) remains uncertain. This study evaluates strength consistency DFS OS PC trials. Methods analysis systematic review meta-analysis followed Preferred Reporting Items Systematic Reviews Meta-Analyses guidelines. Trials involving drug therapy were identified through PubMed, Embase Cochrane...
PURPOSE Early-onset pancreatic cancer (EOPC) is an emerging global health concern, defined as (PC) diagnosed before age 50 years. This study aims to evaluate trends in EOPC incidence, mortality, and associated risk factors, with projections of future burden through 2040. METHODS A population-based analysis was conducted using the Global Burden Diseases, Injuries, Risk Factors Study 2021 data set, encompassing from 204 countries territories. PC individuals 15-49 Statistical analyses...
Dermal sarcomas represent a group or rare malignancies of mesenchymal origin. Although surgical excision with wide margins can be curative, in the advanced/metastatic setting, treatment options are limited and benefit from anthracycline-based chemotherapy targeted agents is usually short-lived. Tumor mutational burden PD-L1 expression scores used as predictive biomarker for response to immunotherapy some metastatic cancers. The role immune-checkpoint blockade sarcoma patients remains...
Oncotype DX (ODX) is a validated assay for the prediction of risk recurrence and benefit chemotherapy (CT) in both node negative (N0) 1-3 positive nodes (N1), hormone receptor (HR+), human epidermal growth factor 2-negative (HER2-) early breast cancer (eBC). Due to limited access genomic assays Brazil, treatment decisions remain largely driven by traditional clinicopathologic factors. ODX has been reported be cost-effective different health system, but data are available considering reality...
Abstract Background An especially significant event in the patient–oncologist relationship is initial consultation, where many complex topics—diagnosis, treatment intent, and often, prognosis—are discussed a relatively short period of time. This study aimed to measure patients' understanding information during their first medical oncology visit satisfaction with communication from oncologists. Methods Between January August 2021, patients without prior systemic gastrointestinal malignancy...
282 Background: Outcomes remain poor for patients with metastatic gastric, gastroesophageal and esophageal adenocarcinoma (GEAC) median survival of 14 months combination chemotherapy immunotherapy as per the Checkmate 649 trial. There is limited data to clarify if any differences exist between denovo recurrent GEAC in terms response systemic therapy. We compare baseline characteristics outcomes our cohort. Methods: A retrospective observational analysis was conducted include reviewed at...
Abstract Background Patient-reported outcomes measures (PROM) are self-reflections of an individual’s physical functioning and emotional well-being. The Edmonton Symptom Assessment Scale (ESAS) is a simple validated PRO tool 10 common symptoms patient-reported functional status (PRFS) measure. prognostic value this unknown in patients with gastroesophageal cancer (GEC). In study, we examined the association between ESAS score overall survival (OS) GEC, prognostication difference Eastern...
2023 Background: Brain metastases (BM) in advanced thyroid cancer are rare; however, they may be underreported as staging brain imaging is not routine. Prognostic features and molecular alterations for this group poorly described. We characterized the clinical of with BM evaluated differences survival. Methods: In single-center retrospective analysis, patients metastatic radioactive iodine refractory well-differentiated, poorly-differentiated, or medullary carcinoma seen at Princess Margaret...
e18822 Background: Oncotype DX (ODX) is a validated tool for the prediction of risk recurrence and benefit chemotherapy (CH) in both node negative (N0) positive (N1), hormone receptor (HR+), HER2 (HER2-) early breast cancer (eBC). Due to limited access novel genomic assays Brazil, treatment decisions remain largely driven by traditional clinicopathologic factors. ODX has been reported be cost-effective, but data available considering reality middle-income countries such as Brazil. We aim...
320 Background: Patient reported outcomes (PRO) measures are accurate self-reflections of an individual’s physical functioning and emotional well-being. The prognostic value is unknown in gastroesophageal (GE) cancer patients (pts). Edmonton Symptom Assessment Scale (ESAS) a simple validated 10-item PRO tool which uses 0 to 10 rating ten common symptoms (total 0-100). In this study, we examined the association between ESAS score overall survival (OS) pts with localized metastatic GE...
302 Background: The majority of esophageal and gastric cancers are diagnosed at an advanced stage with poor overall survival (OS), leading some to propose screening, even in countries a low incidence. Whether diagnostic delay from symptom onset has any impact on OS is unclear. We investigated this question the peri-COVID19 pandemic era. Methods: retrospectively analyzed cohort 308 patients esophageal, gastroesophageal junction, or carcinoma treated curative intent Princess Margaret Cancer...
2029 Background: Brain metastasis (BM) and Leptomeningeal Carcinomatosis (LC) are uncommon complications in gastroesophageal carcinoma (GEC) patients (pts). These have a poor prognosis challenging to study. We described the clinicopathologic features outcomes largest real-world cohort of CNS GEC pts. Methods: conducted single-center retrospective study pts treated at Princess Margaret Cancer Centre from 2007 2021 who developed BM. Clinicopathologic characteristics treatment modalities were...
e16012 Background: Anemia is common in cancer patients and cancer-related anemia has been associated with poorer clinical outcomes various malignancies. The degree of receiving chemotherapy, as a prognostic factor gastroesophageal cancers (GE), not well understood. There have studies looking at scores their efficacy predicting outcomes, which the Gustave Roussy Immune (GRIm-Score) seen to be most predictive early death GE cancers. This study aims compare hemoglobin (g/L) values before...